Previous Article | Next Article ![]()
Molecular and Cellular Biology, March 2001, p. 1682-1687, Vol. 21, No. 5
Department of Physiology, University of
California at San Francisco, San Francisco, California 94143
Received 4 August 2000/Returned for modification 28 September
2000/Accepted 7 December 2000
The actinin-associated LIM protein, ALP, is the prototype of a
large family of proteins containing an N-terminal PDZ domain and a
C-terminal LIM domain. These PDZ-LIM proteins are components of the
muscle cytoskeleton and occur along the Z lines owing to interaction of
the PDZ domain with the spectrin-like repeats of The muscle cytoskeleton comprises a
complex protein network that provides cellular structure and permits
contraction. Disruptions of the myofiber cytoskeleton underlie several
genetic muscular dystrophies, including Duchenne and limb-girdle
muscular dystrophies (8). In addition to these
dystrophin-related disorders, certain inherited muscular dystrophies
are due to mutations in cytoskeletal proteins that do not interact with
the dystrophin complex (15, 18). Identification of the
responsible genes and clarification of mechanisms that regulate the
myofiber cytoskeleton are therefore critical goals.
Recent studies suggest that cytoskeletal elements containing PDZ
protein motifs play important roles in skeletal muscle development and
disease (9). PDZ domains are ~80-amino-acid domains that mediate interactions with either C-terminal or internal binding sites
on target proteins (10, 12, 17, 27). In skeletal muscle,
PDZ domains were first noted in syntrophins and neuronal nitric oxide
synthase (5, 6), which are both components of the
dystrophin-associated glycoprotein complex. Subsequently, a variety of
other PDZ proteins involved in diverse cellular signaling pathways have
been identified in skeletal muscle.
One large family of skeletal muscle PDZ proteins comprises a group of
gene products that contain an N-terminal PDZ domain and one or more
C-terminal LIM domains (21, 23, 32, 33). These PDZ-LIM
proteins associate with the actin cytoskeleton via interaction of their
PDZ domain with the spectrin-like repeats of To address the consequences of ALP deficiency, we generated ALP
knockout mice by homologous recombination in embryonic stem (ES) cells.
The ALP mutant mice are viable and fertile and show no apparent muscle
abnormalities. Despite the absence of ALP protein, muscle histology
appears normal, and muscle sarcolemma is preserved. Furthermore, the
actinin-based cytoskeleton is intact in the knockout mice. These data
suggest that either ALP is not required for skeletal muscle development
and function or an alternative PDZ-LIM protein compensates for the loss
of ALP.
Isolation of ALP genomic DNA and construction of the targeting
vector.
PCR primers based on human ALP (32) were used
to amplify mouse ALP from first-strand cDNA from skeletal muscle. A
bacterial artificial chromosome SV129 mouse genomic library was
screened with the ALP cDNA probe, and three bacterial artificial
chromosome clones were obtained, each about 100 kb in size. One of
these clones was characterized in detail. The genomic region
immediately surrounding the first translated exon, which contains 211 bp and encodes amino acids 1 to 30, was sequenced. The targeting
construct used the pPNT replacement vector (28) and
replaced exon one of ALP with neomycin and was flanked on the two sides
by a total of 6.4 kb of genomic DNA (Fig.
1). The 3.5-kb upstream region was PCR
amplified, digested with KpnI and BamHI, and
subcloned into the KpnI-BamHI sites of the pPNT
vector. The 2.9-kb downstream region was PCR amplified, digested with
NotI, and inserted into the NotI site.
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.5.1682-1687.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Actinin-Associated LIM Protein-Deficient Mice
Maintain Normal Development and Structure of Skeletal Muscle


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-actinin. Because
PDZ and LIM domains are typically found in proteins that mediate
cellular signaling, PDZ-LIM proteins are suspected to participate in
muscle development. Interestingly the ALP gene occurs at 4q35 near the
heterochromatic region mutated in facioscapulohumeral muscular
dystrophy, indicating a possible role for ALP in this disease. Here, we
describe the generation and analysis of mice lacking the ALP gene.
Surprisingly, the ALP knockout mice show no gross histological
abnormalities and maintain sarcolemmal integrity as determined by serum
pyruvate kinase assays. The absence of a dystrophic phenotype in these
mice suggests that down-regulation of ALP does not participate in
facioscapulohumeral muscular dystrophy. These data suggest that ALP
does not participate in muscle development or that an alternative
PDZ-LIM protein can compensate for the lack of ALP.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-actinin; this
interaction targets these PDZ-LIM proteins to the Z lines
(32). The prototypical PDZ-LIM protein in skeletal muscle
is the actinin-associated LIM protein (ALP), which is expressed at
extremely high levels in skeletal muscle and at much lower levels in
cardiac and other tissues (32). Interestingly, the human
ALP gene occurs on chromosome 4q35 near the heterochromatic locus that
is mutated in facioscapulohumeral muscular dystrophy (FSHD)
(1), indicating a possible role for ALP in this disease (32).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

View larger version (31K):
[in a new window]
FIG. 1.
Genomic replacement of the mouse ALP exon 1. (A) The
restriction maps of the wild-type ALP locus, the pPNT-ALP targeting
vector, and the properly targeted locus are shown. Recombination (shown
as large Xs) between the targeting vector and the wild-type locus
eliminated the HSV TK gene and produced the knockout allele. A
BamHI site was engineered to allow the wild-type and
knockout genomic loci to be distinguished. (B) Genomic Southern blots
of ES cell clones. Use of the 5' probe for Southern analysis of a
BamHI digest yielded a 20-kb band from the wild-type allele
and a 11.5-kb band from the mutant allele. Use of the 3' probe for
Southern blots of PstI digests yielded a 4-kb band from the
wild-type allele and a 3-kb band from the mutant allele. Clones 7 and
29 show proper targeting in both BamHI (left) and
PstI (right) digests.
Generation of ALP-null mice.
The targeting vector was
linearized with NheI and ligated to an
NheI-compatible cap oligonucleotide as previously described (20) to seal the ends of the linear fragment. This
construct was electroporated into JM-1 ES cells (24),
which were cultured on neomycin-resistant STO fibroblasts that had been
mitotically inactivated by treatment with mitomycin. After
electroporation and double-drug selection with G418 and
1-(2-deoxy-2-fluoro-
-D-arabinofuranosyl)-5-iodouracil, individual cell colonies were picked, expanded, and analyzed by Southern blotting for proper homologous recombination. Two properly targeted ES cell clones (no. 7 and 29) were injected into mouse blastocysts, and the injected embryos were implanted into surrogate mothers. The resulting male chimeric mice were mated to Black Swiss
mice (Taconic, Germantown, N.Y.). Germ line transmission was obtained
from both injected ES clones.
Genotyping of progeny. To genotype the mutant mice, tail DNA was purified and analyzed by PCR. About 1 to 2 cm of tail tissue was placed in 0.5 ml of 10 mM Tris-HCl (pH 8.0), 25 mM EDTA, 75 mM NaCl, 1% sodium dodecyl sulfate, and proteinase K (0.5 mg/ml). Digestion was done at 55°C with constant rocking for 16 h. The DNA was extracted with phenol-chloroform, precipitated with ethanol, and redissolved in 100 µl of Tris-EDTA. Each DNA sample was analyzed by two different PCRs: one to detect the targeted exon of ALP and one to detect the neo gene. The ALP PCR used oligonucleotides P1 (5'-TCATCACCAGGGTAGGTGTTTTCC-3') and P3 (5'-GACCTTTCTGGCTAATGTGGCTGG-3'), whereas the neo PCR used oligonucleotides P2 (5'-GCTAAAGCGCATGCTCCAGACTGC-3') and P3 (5'-GACCTTTCTGGCTAATGTGGCTGG-3'). The ALP PCR produces a 250-bp fragment, and the neo PCR produces a 290-bp fragment.
Western blotting.
For Western blotting, skeletal muscle was
homogenized in 20 volumes (wt/vol) of buffer containing 25 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 1 mM EGTA, and 1 mM phenylmethylsulfonyl fluoride. Protein extracts were separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis and transferred to polyvinylidine difluoride membranes (Millipore, Bedford, Mass.), which were blocked with 3% bovine serum albumin. Antibodies to ALP or
-actinin (Sigma) were diluted in block solution and were incubated with membranes overnight at 4°C. Western blots were developed using enhanced chemiluminescence as previously described (16). Protein
concentration was determined by the Bradford assay (Bio-Rad Laboratories).
Reverse transcription-PCR. Mice were euthanized by cervical dislocation, and the gastrocnemius and cardiac muscles were isolated. Total RNA was prepared using Trizol reagent (Gibco BRL) and poly(A)+ mRNA was purified from total RNA using Oligotex beads (Qiagen) according to the manufacturer's recommendations. Reverse transcription of mRNA was performed with AMV reverse transcriptase (Roche) and oligo(dT) according to the specifications of the manufacturer. PCR amplification was performed with AmpliTaq Gold (Roche) and the following ALP-specific primers: forward, 5'-ATGATACTGGCTATAGATGGCTTTGGTACG-3', and reverse, 5'-ATAGTTTAGCGGCCGCTTAAGCTTTGGGGTACAGAGTGAC-3'. These primers lie outside the first coding exon and flank the alternatively spliced region of ALP. After an initial incubation at 94°C for 10 min, 40 cycles of the following heating protocol were carried out: 50°C for 1 min, 72°C for 30 s, and 94°C for 1 min. PCR products were resolved on 0.8% agarose gels containing ethidium bromide, and bands were visualized by UV illumination. The ALP primers produce a 948-bp fragment from skeletal muscle ALP and a 702-bp fragment from cardiac muscle ALP. Control PCRs were carried out with the following tubulin primers: forward, 5'-CACGGGTCTCCAGGGCTTCTT-3', and reverse, 5'-CATTTCACCATCTGGTTGGCT-3'. PCR conditions were the same as those used for ALP primers except that the extension time was 15 s and 25 cycles were performed.
Immunohistochemistry.
Mice were euthanized with
pentobarbital, and gastrocnemius muscle was dissected without tissue
perfusion or fixation. Muscle tissue was snap-frozen in a bath of
2-methylbutane cooled with liquid nitrogen. Muscle sections (4- to
10-µm thick) were cut using a cryostat and collected on treated
microscope slides (Plus; Fisher). Following hematoxylin and eosin
staining, muscle cryosections were evaluated for myofiber size and
shape. For immunofluorescent staining, skeletal muscle sections
were postfixed in 2% paraformaldehyde in phosphate-buffered saline.
Tissues were blocked in phosphate-buffered saline containing 1% normal
goat serum. Mouse antibody to
-actinin 2(1 µg/ml) or polyclonal
rabbit antibody to ALP (1 µg/ml) was applied to sections overnight at
4°C. For indirect immunofluorescence, secondary goat anti-mouse Cy-3
or donkey anti-rabbit Cy-3-conjugated antibodies were used according to
the specifications of the manufacturer (Jackson ImmunoResearch Laboratories).
Serum pyruvate kinase assay.
Blood was obtained from the
retroorbital sinus or tail and collected into heparin-treated vials.
Pyruvate kinase assays were performed as described (11) by
incubating serum with buffer containing 110 mM imidazole-HCl (pH 7.4),
165 mM KCl, 0.19 mM
-NADH, 5.5 mM MgCl2, 5.5 mM ADP, 5.5 mM dithiothreitol, 2.5 U of lactate dehydrogenase (Sigma), and 0.25 mM
phosphoenolpyruvate at 30°C and monitoring the loss in absorbance at
340 nm. One unit of pyruvate kinase activity is the amount needed to
consume 1 µmol of
-NADH per min. The appropriate institutional
review committee approved all experimental protocols.
| |
RESULTS |
|---|
|
|
|---|
Generation of ALP-deficient mice. We chose to delete the first coding exon of ALP, as such a disruption is likely to abolish protein expression. The predicted translation of the deleted exon is identical to residues 1 to 30 of human ALP. Using the PCR, we designed a targeting vector that replaces the targeted first exon with a neomycin cassette. This cassette is flanked on the 5' side by a 3.5-kb intronic fragment and on the 3' side by a 2.9-kb intronic fragment. A thymidine kinase cassette was added upstream of the 5' intronic sequence to permit double-drug selection (Fig. 1A).
The targeting vector was linearized with NheI and was electroporated into mouse ES cells, which were then selected with G418 and 1-(2-deoxy-2-fluoro-
-D-arabinofuranosyl)-5-iodouracil.
Double resistant clones were analyzed by Southern blotting and PCR. For this Southern blotting, genomic DNA from the ES cells was digested with
BamHI and probed with a 0.8-kb
HindIII/XbaI fragment (Fig. 1B). Among three
clones that tested positive for homologous recombination with the 5'
probe, two clones were confirmed as positives by PstI digestion, followed by hybridization using a 3' genomic probe (a
0.65-kb NheI/PstI fragment; see Fig. 1B).
Appropriately targeted clones (2 of 96) were injected into blastocytes,
and the resulting chimeric mice were used to breed heterozygous and
homozygous mice, which were genotyped by Southern blotting with a 5'
probe and PCR (Fig. 2A). Heterozygous
mice were intercrossed, and 138 F2 mice were
analyzed, of which 30 (29%) were the wild type, 67 (49%) were
heterozygous, and 41 (22%) were homozygous mutants. This indicates
that ALP knockouts are born at the predicted Mendelian frequency.
Furthermore, both male and female knockout mice are viable, fertile,
and indistinguishable in appearance from their littermates.
|
/
mice. Western blotting was used to assess ALP
protein expression in the mutant mice. Homogenates from gastrocnemius
muscles of wild-type, ALP+/
, and ALP
/
mice were probed with an antibody raised to a full-length ALP protein.
As shown in Fig. 2C, ALP is absent in the knockout mice, although
expression of
-actinin protein is preserved.
ALP deficiency does not disrupt skeletal muscle development.
Skeletal muscle from ALP mutant mice appears normal. Because of the
proximity of ALP to the chromosomal region mutated in FSHD, we examined
muscle histology carefully for signs of dystrophy. In the
mdx mouse model of Duchenne muscular dystrophy, histological hallmarks include necrosis, increased fiber degeneration and/or regeneration with central nuclei, and increased variability in muscle
bundle size and shape (7). For histological studies, we
analyzed hematoxylin and eosin-stained gastrocnemius muscle sections. We found that muscle from ALP mutant mice does not show any of the histopathological changes characteristic of dystrophy, such
as variable myofiber sizes and shapes, centralized nuclei, or
inflammatory infiltrates (Fig. 3A). As a
quantitative measure of myocyte degeneration and/or regeneration, we
counted centrally located nuclei. The percentage of central nuclei in
ALP mutant mice is <1.0% and not different from wild-type
littermates. In mdx mice, >50% of myofibers contain
central nuclei.
|
-actinin at the Z lines of
skeletal muscle, we stained muscle sections from the knockout mice
for
-actinin to evaluate cytoskeletal integrity. In longitudinal sections of wild-type skeletal muscle, ALP closely colocalizes with
-actinin at Z lines. As expected, ALP staining is absent in muscle
from ALP
/
mice (Fig. 3B), although
-actinin
staining of Z lines appears normal (Fig. 3C).
ALP deficiency does not influence sarcolemmal
permeability.
Many muscular dystrophies cause sarcolemmal damage,
which results in leakage of muscle enzymes. Serum pyruvate kinase
levels are extremely elevated in many muscular dystrophy syndromes and are mildly elevated in FSHD (14). In mdx mice,
pyruvate kinase levels rise acutely during the third week of life and
remain elevated for at least 6 months (19). To determine
whether loss of ALP causes sarcolemmal damage, we assayed serum
pyruvate kinase activity of adult wild-type, ALP+/
, and
ALP
/
mice. Serum pyruvate kinase levels in the plasma
of ALP mutant mice were 0.31 ± 0.07 U/ml, not significantly
different from those of the heterozygotes (0.27 ± 0.05 U/ml) or
wild types (0.23 ± 0.05 U/ml), suggesting that sarcolemmal
integrity is intact in ALP mutant mice. (Results are the means of
triplicate assays of plasma samples from 7-month-old mice.)
| |
DISCUSSION |
|---|
|
|
|---|
ALP is a newly recognized component of the muscle cytoskeleton and
localizes to the Z lines owing to interaction of its PDZ domain with
-actinin. ALP is an extremely abundant protein, as its mRNA
represents approximately 0.18% of total mRNA in muscle (22). Expression of ALP is not restricted to skeletal
muscle, as it is readily detected in cardiac muscle as well
(32). Also, ALP is abundant in certain smooth muscles, as
chicken ALP was purified as a major actinin-associated protein from the
gizzard (23). Despite the abundance of ALP in muscle, mice
lacking ALP show normal muscle development and are without visible
muscle abnormalities. Analysis of muscle from these mice demonstrates normal histological parameters. Also, the sarcolemma is not
compromised, as serum pyruvate kinase levels are within normal limits.
These data suggest that ALP is not required for muscle development.
Recent studies have identified a large family of PDZ-LIM proteins that
occur throughout the body. Several PDZ-LIM proteins are expressed in
skeletal muscle and occur at the Z lines through a conserved
interaction of their PDZ domains with
-actinin (21, 23, 32,
33). Because these other PDZ-LIM proteins are quite similar to
ALP, they may compensate for the loss of ALP in the mutant mice.
What is the role for ALP in skeletal muscle? Biochemical and genetic studies have established that PDZ domains typically help assemble signal transduction pathways (10, 12, 17, 27). On the other hand, functions for LIM domains have remained less certain. LIM domains were first characterized in homeodomain transcription factors that determine cellular fate (25). Subsequently, LIM domains have been found in a variety of cytoskeletal proteins that associate with actin (13, 26). The muscle LIM protein (MLP) comprises a pair of LIM domains and, like ALP, is associated with Z lines (2). MLP is a positive regulator of myogenesis, and MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure (3). Whether the LIM domain of ALP has functions similar to the LIM domains of MLP remains uncertain.
Chromosomal mapping studies show that ALP occurs in 4q35, within 7 Mb of the telomeric region that is deleted in FSHD, the most common autosomal dominant muscular dystrophy. Genetic linkage analysis demonstrates that the FSHD locus occurs at 4q35, near the telomere of chromosome 4q (30; M. Upadhyaya, P. W. Lunt, M. Sarfarazi, W. Broadhead, J. Daniels, M. Owen, and P. S. Harper, Letter, Lancet 336:1320-1321, 1990). Both familial and spontaneous FSHD patients often have deletions of an integral number of 3.3-kb tandemly repeated units in this region (29, 31). No transcribed sequences have been found within these repeated units. Taken together, these observations have led to the suggestion that the deletions may mediate position effect variegation and alter the expression of a muscle-specific gene within 4q35 (1).
Studies of ALP expression in FSHD have not demonstrated a reproducible change in diseased muscle (4). However, because FSHD is a dominant disease caused by a heterochromatic mutation, it may be difficult to detect significant changes in steady-state expression levels of the responsible gene. Because of these complex genetics, animal models are needed to ascertain decisively a role for specific gene products in this disease. The normality of ALP knockout mice reported here suggests that down-regulation of ALP expression is unlikely to participate in FSHD. On the other hand, the FSHD mutation may up-regulate nearby transcripts (1), so that analysis of transgenic mice overexpressing ALP or other muscle-specific genes in 4q35 may provide insight.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grants (to D.S.B.) from the National Institutes of Health (R01 NS34822), the Muscular Dystrophy Association, and the Howard Hughes Medical Institute Research Resources Program (76296-549901) and (to R.C.B.) from the American Heart Association Western States Affiliate.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: University of California at San Francisco School of Medicine, 513 Parnassus Ave., San Francisco, CA 94143-0444. Phone: (415) 476-6310. Fax: (415) 476-4929. E-mail: bredt{at}itsa.ucsf.edu.
Present address: LG Chemical, Ltd., Life Science R&D, Taejon, Korea.
Present address: Faculty of Medicine, Maastricht University,
Maastricht, The Netherlands.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Altherr, M. R., U. Bengtsson, R. P. Markovich, and S. T. Winokur. 1995. Efforts toward understanding the molecular basis of facioscapulohumeral muscular dystrophy. Muscle Nerve 2:S32-S38[CrossRef][Medline]. |
| 2. | Arber, S., G. Halder, and P. Caroni. 1994. Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell 79:221-231[CrossRef][Medline]. |
| 3. | Arber, S., J. J. Hunter, J. Ross, Jr., M. Hongo, G. Sansig, J. Borg, J. C. Perriard, K. R. Chien, and P. Caroni. 1997. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88:393-403[CrossRef][Medline]. |
| 4. | Bouju, S., G. Piétu, M. Le Cunff, N. Cros, P. Malzac, J. F. Pellissier, F. Pons, J. J. Léger, C. Auffray, and C. A. Dechesne. 1999. Exclusion of muscle specific actinin-associated LIM protein (ALP) gene from 4q35 facioscapulohumeral muscular dystrophy (FSHD) candidate genes. Neuromuscul. Disord. 9:3-10[CrossRef][Medline]. |
| 5. | Brenman, J. E., D. S. Chao, H. Xia, K. Aldape, and D. S. Bredt. 1995. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82:743-752[CrossRef][Medline]. |
| 6. |
Brenman, J. E.,
D. S. Chao,
S. H. Gee,
A. W. McGee,
S. E. Craven,
D. R. Santillano,
F. Huang,
H. Xia,
M. F. Peters,
S. C. Froehner, and D. S. Bredt.
1996.
Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and -1 syntrophin mediated by PDZ motifs.
Cell
84:757-767[CrossRef][Medline].
|
| 7. |
Bulfield, G.,
W. G. Siller,
P. A. Wight, and K. J. Moore.
1984.
X chromosome-linked muscular dystrophy (mdx) in the mouse.
Proc. Natl. Acad. Sci. USA
81:1189-1192 |
| 8. | Campbell, K. P. 1995. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80:675-679[CrossRef][Medline]. |
| 9. | Christopherson, K. S., and D. S. Bredt. 1997. Nitric oxide in excitable tissues: physiological roles and disease. J. Clin. Investig. 100:2424-2429[Medline]. |
| 10. | Craven, S. E., and D. S. Bredt. 1998. PDZ proteins organize synaptic signaling pathways. Cell 93:495-498[CrossRef][Medline]. |
| 11. |
Edwards, R. J., and D. C. Watts.
1981.
Specific spectrophotometric assay for the M isoenzymes of pyruvate kinase in plasma samples containing mixtures of the muscle (M) and liver (L) isoenzymes.
Clin. Chem.
27:906-909 |
| 12. | Garner, C. C., J. Nash, and R. L. Huganir. 2000. PDZ domains in synapse assembly and signalling. Trends Cell Biol. 10:274-280[CrossRef][Medline]. |
| 13. | Gill, G. N. 1995. The enigma of LIM domains. Structure 3:1285-1289[Medline]. |
| 14. | Griggs, R. C., J. R. Mendell, and R. G. Miller. 1995. Evaluation and treatment of myopathies. F. A. Davis Company, Philadelphia, Pa. |
| 15. | Hoffman, E. P., F. Lehmann-Horn, and R. Rudel. 1995. Overexcited or inactive: ion channels in muscle disease. Cell 80:681-686[CrossRef][Medline]. |
| 16. |
Jo, K.,
R. Derin,
M. Li, and D. S. Bredt.
1999.
Characterization of MALS/Velis-1, -2, and -3: a family of mammalian LIN-7 homologs enriched at brain synapses in association with the postsynaptic density-95/NMDA receptor postsynaptic complex.
J. Neurosci.
19:4189-4199 |
| 17. | Kornau, H.-C., P. H. Seeburg, and M. B. Kennedy. 1997. Interaction of ion channels and receptors with PDZ domains. Curr. Opin. Neurobiol. 7:368-373[CrossRef][Medline]. |
| 18. | Liu, J., M. Aoki, I. Illa, C. Wu, M. Fardeau, C. Angelini, C. Serrano, J. A. Urtizberea, F. Hentati, M. B. Hamida, S. Bohlega, E. J. Culper, A. A. Amato, K. Bossie, J. Oeltjen, K. Bejaoui, D. McKenna-Yasek, B. A. Hosler, E. Schurr, K. Arahata, P. J. de Jong, and R. H. Brown, Jr. 1998. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat. Genet. 20:31-36[CrossRef][Medline]. |
| 19. | McArdle, A., R. H. Edwards, and M. J. Jackson. 1994. Time course of changes in plasma membrane permeability in the dystrophin-deficient mdx mouse. Muscle Nerve 17:1378-1384[CrossRef][Medline]. |
| 20. | Nehls, M., B. Kyewski, M. Messerle, R. Waldschütz, K. Schüddekopf, A. J. Smith, and T. Boehm. 1996. Two genetically separable steps in the differentiation of thymic epithelium. Science 272:886-889[Abstract]. |
| 21. | Passier, R., J. A. Richardson, and E. N. Olson. 2000. Oracle, a novel PDZ-LIM domain protein expressed in heart and skeletal muscle. Mech. Dev. 92:277-284[CrossRef][Medline]. |
| 22. |
Piétu, G.,
O. Alibert,
V. Guichard,
B. Lamy,
F. Bois,
E. Leroy,
R. Mariage-Sampson,
R. Houlgatte,
P. Soularue, and C. Auffray.
1996.
Novel gene transcripts preferentially expressed in human muscles revealed by quantitative hybridization of a high density cDNA array.
Genome Res.
6:492-503 |
| 23. |
Pomiès, P.,
T. Macalma, and M. C. Beckerle.
1999.
Purification and characterization of an alpha-actinin-binding PDZ-LIM protein that is up-regulated during muscle differentiation.
J. Biol. Chem.
274:29242-29250 |
| 24. | Qiu, M., A. Bulfone, I. Ghattas, J. J. Meneses, L. Christensen, P. T. Sharpe, R. Presley, R. A. Pedersen, and J. L. Rubenstein. 1997. Role of the Dlx homeobox genes in proximodistal patterning of the branchial arches: mutations of Dlx-1, Dlx-2, and Dlx-1 and -2 alter morphogenesis of proximal skeletal and soft tissue structures derived from the first and second arches. Dev. Biol. 185:165-184[CrossRef][Medline]. |
| 25. | Sanchez-Garcia, I., and T. H. Rabbitts. 1994. The LIM domain: a new structural motif found in zinc-finger-like proteins. Trends Genet. 10:315-320[CrossRef][Medline]. |
| 26. | Schmeichel, K. L., and M. C. Beckerle. 1994. The LIM domain is a modular protein-binding interface. Cell 79:211-219[CrossRef][Medline]. |
| 27. | Sheng, M. 1996. PDZs and receptor/channel clustering: rounding up the latest suspects. Neuron 17:575-578[CrossRef][Medline]. |
| 28. | Tybulewicz, V. L., C. E. Crawford, P. K. Jackson, R. T. Bronson, and R. C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163[CrossRef][Medline]. |
| 29. |
van Deutekom, J. C.,
C. Wijmenga,
E. A. van Tienhoven,
A. M. Gruter,
J. E. Hewitt,
G. W. Padberg,
G. J. van Ommen,
M. H. Hofker, and R. R. Frants.
1993.
FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit.
Hum. Mol. Genet.
2:2037-2042 |
| 30. | Wijmenga, C., R. R. Frants, O. F. Brouwer, P. Moerer, J. L. Weber, and G. W. Padberg. 1990. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 336:651-653[CrossRef][Medline]. |
| 31. | Wijmenga, C., J. E. Hewitt, L. A. Sandkuijl, L. N. Clark, T. J. Wright, H. G. Dauwerse, A. M. Gruter, M. H. Hofker, P. Moerer, R. Williamson, et al. 1992. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat. Genet. 2:26-30[CrossRef][Medline]. |
| 32. |
Xia, H.,
S. T. Winokur,
W. L. Kuo,
M. R. Altherr, and D. S. Bredt.
1997.
Actinin-associated LIM protein: identification of a domain interaction between PDZ and spectrin-like repeat motifs.
J. Cell Biol.
139:507-515 |
| 33. |
Zhou, Q.,
P. Ruiz-Lozano,
M. E. Martone, and J. Chen.
1999.
Cypher, a striated muscle-restricted PDZ and LIM domain-containing protein, binds to alpha-actinin-2 and protein kinase C.
J. Biol. Chem.
274:19807-19813 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»